Cochrane Risk Of Bias Tool For Non-Randomized Studies
Like many others, our position is that, with very few exceptions, cause and effect conclusions regarding therapeutic interventions can only be drawn when valid RCT data exists. However, there are uses for observational studies which may be used to answer additional questions, and non-randomized studies (NRS) are often included in systematic reviews.
In September 2014, Cochrane published a tool for assessing bias in NRS for systematic review authors . It may be of interest to our colleagues. The tool is called ACROBAT-NRSI (“A Cochrane Risk Of Bias Assessment Tool for Non-Randomized Studies”) and is designed to assist with evaluating the risk of bias (RoB) in the results of NRS that compare the health effects of two or more interventions.
The tool focuses on internal validity. It covers seven domains through which bias might be introduced into a NRS. The domains provide a framework for considering any type of NRS, and are summarized in the table below, and many of the biases listed here are described and explanations of how they may cause bias are presented in the full document, and you can see our rough summary here: http://www.delfini.org/delfiniClick_Observations.htm#robtable
Response options for each bias include: low risk of bias; moderate risk of bias; serious risk of bias; critical risk of bias; and no information on which to base a judgment.
Details are available in the full document which can be downloaded at—https://sites.google.com/site/riskofbiastool/
We again point out that non-randomized studies often report seriously misleading results even when treated and control groups appear similar in prognostic variables and agree with Deeks that, for therapeutic interventions ,“non-randomised studies should only be undertaken when RCTs are infeasible or unethical”—and even then, buyer beware. Studies do not get “validity grace” because of scientific or practical challenges.
Furthermore, we are uncertain that this tool is of great value when assessing NRS. Deeks  identified 194 tools that could be or had been used to assess NRS. Do we really need another one? While it’s a good document for background reading, we are more comfortable approaching the problem of observational data by pointing out that, when it comes to efficacy, high quality RCTs have a positive predictive value of about 85% whereas well-done observational trials have a positive predictive value of about 20% .
Sterne JAC, Higins JPT, Reves BC on behalf of the development group for ACROBAT- NRSI. A Cochrane Risk Of Bias Asesment Tol: for Non-Randomized Studies of Interventions (ACROBAT- NRSI), Version 1.0.0, 24 September 2014. Available from htp:/www.riskofbias.info [accessed 10/11/14.
Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):iii-x, 1-173. Review. PubMed PMID: 14499048.
Ioannidis JPA. Why Most Published Research Findings are False. PLoS Med 2005; 2(8):696-701 PMID: 16060722.